It has been one year since Lipitor lost its patent protection, and now several firms are progressing towards the next generation of medicines for reducing LDL, otherwise known as “bad cholesterol.” A sizable amount of interest is concentrated on the cholesterol-regulating gene PCSK9 in the liver, with Amgen (NASDAQ:AMGN) and Pfizer (NYSE:PFE) on Monday presenting data which indicates that their drugs performed well in mid-stage trials. meanwhile, Sanofi-aventis (NYSE:SNY) and its partner Regeneron Pharmaceuticals (NASDAQ:REGN) reported a massive Phase III trial for their treatment.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Staff members at the FDA report that Novo Nordisk’s (NYSE:NVO) ultra long-acting insulin degludec seems to increase the risk of cardiovascular death, along with non-fatal heart attacks, strokes and unstable angina by 30 percent relative to comparators, although there exists a large uncertainty regarding the statistical margin of error. An FDA advisory panel is scheduled to vote on Thursday on recommendation.
Don’t Miss: Here’s How Pfizer Will Get Over Lipitor Loss.